Jemperli approved in the U.S. for certain rectal cancer patients
Jemperli (dostarlimab) was approved in the U.S. for adults with MSI-H/dMMR locally advanced rectal cancer, described as the first and only immunotherapy for this indication.
Jemperli (dostarlimab) was approved in the U.S. for adults with MSI-H/dMMR locally advanced rectal cancer, described as the first and only immunotherapy for this indication.